Trials / No Longer Available
No Longer AvailableNCT03801278
An Expanded Access Study of Bemarituzumab (FPA144) for a Single Patient With Recurrent Bladder Cancer
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Five Prime Therapeutics, Inc. · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This is an open-label, expanded access protocol to continue administration of bemarituzumab (FPA144) in a single patient with recurrent bladder cancer
Detailed description
This protocol is intended to provide access to bemarituzumab (FPA144 an investigational agent) to a single patient with recurrent bladder cancer who had a response to study drug on FPA144-001. That study is closing and this expanded access protocol allows this single patient to continue receiving this agent.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FPA144 | Bemarituzumab administration every two weeks |
Timeline
- First posted
- 2019-01-11
- Last updated
- 2021-12-13
Source: ClinicalTrials.gov record NCT03801278. Inclusion in this directory is not an endorsement.